Aerie Pharmaceuticals - Public Company Showcase at Ophthalmology Innovation Summit @ ASRS 2019 скачать в хорошем качестве

Aerie Pharmaceuticals - Public Company Showcase at Ophthalmology Innovation Summit @ ASRS 2019

Casey Kopczynski, PhD, Co-Founder & Chief Scientific Officer speaks for Aerie Pharmaceuticals during the Public Company Showcase at OIS@ASRS 2019. REGISTER for our next ophthalmology conference today http://bit.ly/2yFA6cv. Casey Kopczynski, PhD, Co-Founder & Chief Scientific Officer, says Aerie is focused on bringing innovative treatments to eye disease. They’ve launched two products, Rhopressa and Rocklatan, for the reduction of intraocular pressure in patients with glaucoma. The active ingredient in Rhopressa is netarsudil, a Rho kinase inhibitor, which was the first new mechanism of action drug for glaucoma in over 20 years. The second product, Rocklatan, is a combination of netarsudil with latanoprost. It’s the first product to be approved based on demonstrating superiority to a prostaglandin analog, the most widely prescribed drug class in glaucoma. Dr. Kopczynski discussed two product candidates in Aerie’s retina program pipeline, AR-13503 and AR-1105, and the company’s sustained delivery technology. He said their pipeline is diverse, and driven by their expertise in small molecule drug discovery. Aerie’s approach to retinal disease is to bring small molecule therapy to treatment of the back of the eye. Most drugs currently being used for treatment of retinal disease are large molecules, and small molecule therapy can address a wider array of targets. However small molecules are rapidly cleared after injection, so require a sustained delivery method, which Aerie has established with a sustained release implant. This presentation takes place at OIS@ASRS at the Ritz-Carlton in Chicago on July 25, 2019. Download the presentation here: https://ois.net/wp-content/uploads/20... WEBSITE https://ois.net FOLLOW Ophthalmology Innovation Summit On Social Media: ► Facebook:   / ois.net   ► Twitter:   / oistweets   JOIN Our Group For Ophthalmology Innovation & Investment On LinkedIn   / 2189664   SUBSCRIBE To Our Weekly OIS Newsletter http://bit.ly/2yFOXUt VIEW Our Past Ophthalmology Event Conferences: http://bit.ly/2yJ4Qts REGISTER For Our Next Conference: http://bit.ly/2yFA6cv #OIS #Ophthalmology #Healthcare _________________________________________________________________ About OIS Ophthalmology Innovation Summit, or OIS for short, facilitates meaningful interactions and the exchange of information between clinical, capital, and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs. The Ophthalmology Innovation Summit programs are presented annually by Healthegy, Inc. as affiliate meetings with American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), Southeastern Congress of Optometry (SECO), and American Society of Retina Specialists (ASRS). ____________________________________________________________________ Healthegy also is the producer of Aesthetics Innovation Summit (AIS), which unites the clinical, corporate and capital leaders to facilitate the exchange of insights on emerging trends while showcasing exciting new drugs, devices, and technologies for the aesthetics market which is projected to double by 2025. ► Website: https://attendais.com ► Facebook:   / aestheticsinnovationsummit   ► Instagram:   / ais_summit   ► Twitter:   / ais_summit   ► Healthegy Website: https://healthegy.com